News
The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.
In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...
The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...
New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
6d
Clinical Trials Arena on MSNPerioperative Padcev and Keytruda improves survival in MIBC
P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...
A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s prostate cancer was recently labelled “aggressive” and described as having ...
The new sites within the MyHealthTeam portfolio, include: Endometrial cancer, a type of uterine cancer, is the most common ...
22h
ZME Science on MSNA Pretzel-Shaped Implant Erased Bladder Cancer In More Than 80 Percent Of Patients
Bladder cancer patients who run out of options often face a grim choice: life-altering surgery to remove the bladder, or living with a disease that might kill them if it spreads to the rest of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results